FDA Regulation of Cannabis-Derived Products

What the FDA actually regulates

The FDA regulates drugs, foods, dietary supplements, cosmetics, animal products, and tobacco under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Cannabis and cannabis-derived compounds fall under FDA oversight whenever they are marketed for any of those uses ^[1]. Separately, the Drug Enforcement Administration (DEA) controls scheduling under the Controlled Substances Act. The 2018 Farm Bill removed 'hemp' — cannabis containing no more than 0.3% delta-9 THC by dry weight — from the CSA, but it explicitly preserved FDA authority over hemp-derived products ^[2].

In practice this means: hemp can be legally grown, but putting hemp-derived CBD into a brownie or a capsule sold as a supplement is a separate question governed by the FD&C Act, not the Farm Bill.

Approved cannabis and cannabinoid drugs

Only one cannabis-derived drug has been approved by the FDA: Epidiolex, a purified plant-derived cannabidiol (CBD) solution approved in 2018 for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex ^[3]. Strong evidence

Three synthetic cannabinoid drugs are also approved:

• Marinol (dronabinol, synthetic THC) — capsules, approved 1985 for chemotherapy-induced nausea and AIDS anorexia.
• Syndros (dronabinol oral solution) — approved 2016.
• Cesamet (nabilone, a synthetic THC analog) — approved 1985 for chemo-induced nausea ^[1].

No whole-plant cannabis product is FDA-approved. 'Medical marijuana' programs operate under state law and are not FDA-recognized medicines.

CBD in food, supplements, and cosmetics

This is where most public confusion lives. The FDA's position, repeated consistently since 2018:

• CBD cannot be sold as a dietary supplement. Under FD&C Act §301(ll) and the 'drug exclusion rule,' once a substance has been approved as a drug or studied in substantial public clinical investigations as a drug, it cannot then be marketed as a dietary supplement. CBD meets both conditions ^[4].
• CBD cannot legally be added to human or animal food sold in interstate commerce, for the same reason ^[4].
• Cosmetics containing CBD are in a grayer zone — cosmetics don't require pre-market approval — but they cannot make therapeutic claims without becoming unapproved drugs ^[1].

In January 2023, the FDA announced it had concluded that a new regulatory pathway for CBD is needed because existing food and supplement frameworks are not appropriate, and asked Congress to act. It also denied three citizen petitions seeking to allow CBD as a supplement ^[5]. As of the last-verified date, Congress has not passed such a framework.

The agency has, however, sent dozens of warning letters — primarily to companies making explicit disease claims (cancer, Alzheimer's, COVID-19, opioid withdrawal) or selling CBD products marketed to children, pets, or as conventional foods ^[6].

Delta-8 THC and intoxicating hemp-derived cannabinoids

The 2018 Farm Bill defined hemp by delta-9 THC content only. That created a loophole: cannabinoids like delta-8 THC, delta-10 THC, THC-O, HHC, and high-dose hemp-derived delta-9 edibles (legal as long as delta-9 stays under 0.3% by dry weight) are sold nationally outside any cannabis regulatory system.

The FDA has issued warning letters about delta-8 products, particularly those marketed in packaging that appeals to children, and has flagged poison-control reports of adverse events ^[7]. The DEA has taken the position that synthetically derived delta-8 (most commercial delta-8 is converted from CBD in a lab) is a controlled substance, though this is contested in court Disputed. State responses vary widely.

The practical situation: these products exist in a legal gray zone the FDA has not resolved and largely does not test, label-verify, or quality-control.

Enforcement reality

FDA enforcement against CBD and hemp-derived products has been selective rather than systematic. The agency's typical actions ^[6]:

1. Warning letters for egregious disease claims or marketing to vulnerable populations.
2. Joint letters with the FTC targeting deceptive advertising.
3. Import alerts on cannabis-containing products.

What the FDA generally has not done: pull every CBD tincture from shelves, prosecute mainstream retailers, or audit CBD product labels for cannabinoid content accuracy — even though independent studies have repeatedly found significant label inaccuracies in CBD products ^[8]. Strong evidence

This gap between the letter of the law and enforcement reality is why CBD is simultaneously 'illegal' and available at every gas station.

What this means in practice

If you're a consumer: an 'FDA-registered facility' label means the facility filed paperwork — it does not mean the FDA approved, inspected, or endorses the product. Only Epidiolex carries genuine FDA approval among cannabis-derived products.

If you're a business: selling CBD as a supplement or food ingredient is technically prohibited under federal law regardless of state law, and the FTC actively polices health claims even when the FDA doesn't.

If you're tracking policy: the meaningful question is whether Congress passes a hemp/CBD regulatory framework (multiple bills have been introduced) and whether the DEA reschedules cannabis from Schedule I to Schedule III following HHS's 2023 recommendation ^[9]. Rescheduling would not by itself legalize state cannabis markets or make CBD a legal supplement, but it would change the research and tax landscape substantially.

---

This article is informational and is not legal advice. Regulations change; consult a licensed attorney in your jurisdiction before making business or compliance decisions. Last verified: June 2024.

Sources

How this page was made